

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

09 Jun 2026

### Effect of symbiotic supplement on serum adiponectin, hs-CRP, TNF- $\alpha$ , Apo A1 and Apo-B100 concentration in obese and overweight breast cancer survivors with low calorie diet

#### Protocol summary

##### Study aim

Effect of symbiotic supplement on serum adiponectin, Apo A1, TNF- $\alpha$ , hs-CRP and Apo B100 concentration in obese and overweight breast cancer survivors with the low-calorie diet.

##### Design

randomized, double-blind, consumption of placebo in control group, single center

##### Settings and conduct

Recruiting and performing the study will take place in oncologist's clinic. participants are randomly divided into intervention and control groups. participants, researchers, and analyser are blinded about groups of study.

##### Participants/Inclusion and exclusion criteria

participants: Breast cancer survivors Main Inclusion criteria: 1- Female breast cancer survivors 2- Age range (50-75) 3- BMI = 25 - 40 Kg/m<sup>2</sup> 4- At least one month has passed since the last radiotherapy 5- Type of breast cancer ER/PR+ and HER2- Main Exclusion criteria: 1- Metastasis during the study 2- Failure to follow the weight loss diet 3-Consumption less than 46 capsules of 56 capsules at the end of the study

##### Intervention groups

Intervention group: Participants in this group follow the weigh loss diet like control group. Calorie intake of participants is calculated base on Harris-Benedict Formula. The recommended amount of calories from each nutrient during the day will be based on : carbohydrates 65-55%, fat 35-20% and protein 15-10% of the calories) + consumption of symbiotic supplement consists of (Lactobacillus casei, Lactobacillus Rhamnosus, Lactobacillus Bulgaricus, Bifidobacterium breve, Bifidobacterium langum, Streptococcus thermophilus + Fructooligosaccharide) microbial population : 1010 CFU/gr and 38/5 mg fructooligosaccharide, once daily for 8 weeks. symbiotic

supplement will be purchase from Zist takhmir company.  
Control group: weight loss diet + placebo

##### Main outcome variables

Primary outcome: Adiponectin Secondary outcomes: TNF-alpha; hs-CRP; Apo-A1, and Apo-B100

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20091114002709N49**  
Registration date: **2018-05-18, 1397/02/28**  
Registration timing: **prospective**

Last update: **2018-05-18, 1397/02/28**

Update count: **0**

##### Registration date

2018-05-18, 1397/02/28

##### Registrant information

##### Name

Farzad Shidfar

##### Name of organization / entity

Iran University of Medical Sciences

##### Country

Iran (Islamic Republic of)

##### Phone

+98 21 8862 2755

##### Email address

shidfar.f@iums.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2018-05-30, 1397/03/09

##### Expected recruitment end date

2018-11-30, 1397/09/09  
**Actual recruitment start date**  
empty  
**Actual recruitment end date**  
empty  
**Trial completion date**  
empty

**Scientific title**  
Effect of symbiotic supplement on serum adiponectin, hs-CRP, TNF- $\alpha$ , Apo A1 and Apo-B100 concentration in obese and overweight breast cancer survivors with low calorie diet

**Public title**  
Effect of symbiotic supplement on breast cancer recurrence

**Purpose**  
Prevention

**Inclusion/Exclusion criteria**  
**Inclusion criteria:**  
Female breast cancer survivors (or Cessation of menstruation for at least 6 months prior to chemotherapy) Age range (50-75) BMI = 25 - 40 Kg/m<sup>2</sup> At least one month has passed since the last radiotherapy Complete treatment of stage 1 - 4 breast cancer survivors Type of breast cancer : ER/PR+ and HER2- Willingness to cooperate and sign a written informed consent  
**Exclusion criteria:**  
History of Diabetes, acute heart failure, cirrhosis hepatic, acute and chronic renal failure History of autoimmune and infectious disease weight loss diet during the 6 months prior to study Smoking Alcohol consumption Nutrition supplement consumption

**Age**  
From **50 years** old to **75 years** old

**Gender**  
Female

**Phase**  
N/A

**Groups that have been masked**

- Participant
- Care provider
- Investigator
- Outcome assessor
- Data analyser

**Sample size**  
Target sample size: **76**

**Randomization (investigator's opinion)**  
Randomized

**Randomization description**  
use of stratified randomization based on BMI (BMI=25-30 and BMI=30-40)

**Blinding (investigator's opinion)**  
Double blinded

**Blinding description**  
In this study, participants, major researcher, data collectors were kept blind to study groups.

**Placebo**  
Used

**Assignment**  
Parallel  
**Other design features**

**Secondary Ids**  
empty

## Ethics committees

1

### Ethics committee

#### Name of ethics committee

Ethics committee of Iran University of Medical Science

#### Street address

Martyr Hemmat Highway, the highway of Sheikh Fazlullah Nuri and martyr Chamran

#### City

Tehran

#### Province

Tehran

#### Postal code

۱۴۳۹۶۱۴۵۳۵

### Approval date

2018-04-20, 1397/01/31

### Ethics committee reference number

IR.IUMS.REC1397.32557

## Health conditions studied

1

### Description of health condition studied

Breast cancer

### ICD-10 code

C50

### ICD-10 code description

Malignant neoplasm of breast

## Primary outcomes

1

### Description

Adiponectin

### Timepoint

Before intervention and 8 weeks after the start of intervention

### Method of measurement

Elisa method

## Secondary outcomes

1

### Description

Tumor Necrosis Factor alpha (TNF- $\alpha$ )

### Timepoint

Before intervention and 8 weeks after the start of intervention

## Method of measurement

Elisa method

## 2

### Description

high-sensitivity C-reactive protein (hs-CRP)

### Timepoint

Before intervention and 8 weeks after the start of intervention

### Method of measurement

Elisa method

## 3

### Description

Apolipoprotein-A1 (Apo-A1)

### Timepoint

Before intervention and 8 weeks after the start of intervention

### Method of measurement

Elisa method

## 4

### Description

Apolipoprotein-B100 (Apo-B100)

### Timepoint

Before intervention and 8 weeks after the start of intervention

### Method of measurement

Elisa method

## Intervention groups

## 1

### Description

Intervention group: Intervention group: Weight loss diet consultation (At the beginning of the study all the participants, according to their age, height, weight and calculating Energy Expenditure , should follow the weight loss diet which results in reduction in body weight about 0.5 to 1 kg per week. Participants in both; intervention and control groups refer to the dietitian in the doctor najafi's clinic one time every four weeks to change their diet. Calorie intake of participants is calculated base on Harris-Benedict Formula. The recommended amount of calories from each nutrient during the day will be based on : carbohydrates 65-55%, fat 35-20% and protein 15-10% of the calories) + consumption of symbiotic supplement consists of (Lactobacillus casei, Lactobacillus Rhamnosus, Lactobacillus Bulgaricus, Bifidobacterium breve, Bifidobacterium langum, Streptococcus thermophilus + Fructooligosaccharide) microbial population : 1010 CFU/gr and 38/5 mg fructooligosaccharide, once daily for 8 weeks. symbiotic supplement will be purchase from Zist takhmir company.

### Category

Treatment - Drugs

## 2

### Description

Control group : weight loss diet consultation (At the beginning of the study all the participants, according to their age, height, weight and calculating Energy Expenditure , should follow the weight loss diet which results in reduction in body weight about 0.5 to 1 kg per week. Participants in both; intervention and control groups refer to the dietitian in the doctor najafi's clinic one time every four weeks to change their diet. Calorie intake of participants is calculated based on Harris-Benedict Formula. The recommended amount of calories from each nutrient during the day will be based on : carbohydrates 65-55%, fat 35-20% and protein 15-10% of the calories) + placebo consists of ( lactose,Magnesium Stearate, talk, silicon dioxide) once daily for 8 weeks. Placebo will be purchase from Zist takhmir company.

### Category

Placebo

## Recruitment centers

## 1

### Recruitment center

#### Name of recruitment center

Dr Safa Najafi Clinic

#### Full name of responsible person

Dr Safa Najafi

#### Street address

Doctor's building number 3, unit 11, Molasadra Street, Vanak Square

#### City

Tehran

#### Province

Tehran

#### Postal code

1234561

#### Phone

+98 21 4401 3375

#### Email

rajimahsa@yahoo.com

## Sponsors / Funding sources

## 1

### Sponsor

#### Name of organization / entity

Iran University of Medical Sciences

#### Full name of responsible person

Doctor seyed Javad ali Mosavai

#### Street address

Martyr Hemmat Highway, the highway of Sheikh Fazlullah Nuri and martyr Chamran

#### City

Tehran

#### Province

Tehran

#### Postal code

۱۳۴۹۶۱۴۵۳۵

**Phone**

+98 21 86701

**Email**

rajimahsa@yahoo.com

**Grant name**

Grant Masters Selected Research Week

**Grant code / Reference number**

**Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Iran University of Medical Sciences

**Proportion provided by this source**

100

**Public or private sector**

Public

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding**

*empty*

**Country of origin**

**Type of organization providing the funding**

Academic

**Person responsible for general inquiries**

**Contact**

**Name of organization / entity**

Iran University of Medical Sciences

**Full name of responsible person**

Mahsa Raji Lahiji

**Position**

Student / Nutrition master

**Latest degree**

Bachelor

**Other areas of specialty/work**

Nutrition

**Street address**

Martyr Hemmat Highway, the Highway of Sheikh Fazullah Nuri and martyr Chamran, School of public health , nutrition group

**City**

Tehran

**Province**

Tehran

**Postal code**

۱۳۴۹۶۱۴۵۳۵

**Phone**

+98 21 4401 3375

**Email**

Rajimahsa@yahoo.com

**Person responsible for scientific inquiries**

**Contact**

**Name of organization / entity**

Iran University of Medical Sciences

**Full name of responsible person**

Doctor Mitra Zarrati

**Position**

PHD nutrition/ Science committee of Nutrition group

**Latest degree**

Ph.D.

**Other areas of specialty/work**

Nutrition

**Street address**

Martyr Hemmat Highway, the highway of Sheikh Fazlullah Nuri and martyr Chamran, school of public health, nutrition group

**City**

Tehran

**Province**

Tehran

**Postal code**

۱۳۴۹۶۱۴۵۳۵

**Phone**

+98 21 8670 4814

**Email**

zarrati-ms@yahoo.com

**Person responsible for updating data**

**Contact**

**Name of organization / entity**

Iran University of Medical Sciences

**Full name of responsible person**

Mahsa Raji Lahiji

**Position**

Student / Nutrition master

**Latest degree**

Bachelor

**Other areas of specialty/work**

Nutrition

**Street address**

Martyr Hemmat Highway, the Highway of Sheikh Fazullah Nuri and martyr Chamran, School of public health , nutrition group

**City**

Tehran

**Province**

Tehran

**Postal code**

۸۶۷۰۱۰۰۲۱

**Phone**

+98 21 4401 3375

**Email**

rajimahsa95@yahoo.com

**Sharing plan**

**Deidentified Individual Participant Data Set (IPD)**

No - There is not a plan to make this available

**Justification/reason for indecision/not sharing IPD**

participants privacy security

**Study Protocol**

No - There is not a plan to make this available

**Statistical Analysis Plan**

No - There is not a plan to make this available

**Informed Consent Form**

No - There is not a plan to make this available

**Clinical Study Report**

Undecided - It is not yet known if there will be a plan to

make this available

**Analytic Code**

No - There is not a plan to make this available

**Data Dictionary**

No - There is not a plan to make this available